Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 5/2015

01-10-2015 | Review

Ageing with HIV: a multidisciplinary review

Authors: A. Calcagno, S. Nozza, C. Muss, B. M. Celesia, F. Carli, S. Piconi, G. V. De Socio, A. M. Cattelan, G. Orofino, D. Ripamonti, A. Riva, G. Di Perri

Published in: Infection | Issue 5/2015

Login to get access

Abstract

Introduction

After the introduction of highly active antiretroviral treatment, the course of HIV infection turned into a chronic disease and most of HIV-positive patients will soon be over 50 years old.

Material and methods

This paper reviews the multiple aspects that physicians have to face while taking care of HIV-positive ageing patients including the definitions of frailty and the prevalence and risk factors of concomitant diseases. From a therapeutic point of view pharmacokinetic changes and antiretroviral-specific toxicities associated with ageing are discussed; finally therapeutic approaches to frailty are reviewed both in HIV-positive and negative patients.

Conclusion and discussion

We conclude by suggesting that the combined use of drugs with the least toxicity potential and the promotion of healthy behaviours (including appropriate nutrition and exercise) might be the best practice for ageing HIV-positive subjects.
Appendix
Available only for authorised users
Literature
1.
Centers for Disease Control–CDC (USA). AIDS among persons aged > or = 50 years—United States, 1991–1996. MMWR Morb Mortal Wkly Rep. 1998;47:21–7.
2.
Brothers TD, Rockwood K. Biologic aging, frailty, and age-related disease in chronic HIV infection. Curr Opin HIV AIDS. 2014;9:412–8.PubMedCrossRef
3.
4.
Thomas DR. Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr. 2007;26:389–99.PubMedCrossRef
5.
McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, Aldrovandi GM, Cardoso SW, Santana JL, Brown TT. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937–46.PubMedCentralPubMedCrossRef
6.
Michaud M, Balardy L, Moulis G, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc. 2013;14:877–82.PubMedCrossRef
7.
Young B, Dao CN, Buchacz K, et al. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006. Clin Infect Dis. 2011;52:1061–8.PubMedCrossRef
8.
9.
Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, Margolick JB. Multicenter AIDS Cohort Study. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci. 2007;62:1279–86.PubMedCrossRef
10.
Detels R, Jacobson L, Margolick J, Martinez-Maza O, Muñoz A, Phair J, Rinaldo C, Wolinsky S. The multicenter AIDS Cohort Study, 1983 to …. Public Health. 2012;126:196–8.PubMedCentralPubMedCrossRef
11.
Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, Goulet J, Simberkoff M, Butt AA, Rimland D, Rodriguez-Barradas MC, Gibert CL, Oursler KA, Brown S, Leaf DA, Goetz MB, Bryant K. Veterans Aging Cohort Study (VACS): overview and description. Med Care. 2006;44:S13–24.PubMedCentralPubMedCrossRef
12.
Womack JA, Goulet JL, Gibert C, Brandt CA, Skanderson M, Gulanski B, Rimland D, Rodriguez-Barradas MC, Tate J, Yin MT, Justice AC. Veterans Aging Cohort Study Project Team. Physiologic frailty and fragility fracture in HIV infected male veterans. Clin Infect Dis. 2013;56:1498–504.PubMedCentralPubMedCrossRef
13.
Onen NF, Agbebi A, Shacham E, Stamm KE, Onen AR, Overton ET. Frailty among HIV-infected persons in an urban outpatient care setting. J Infect. 2009;59:346–52.PubMedCrossRef
14.
Piggott DA, Muzaale AD, Mehta SH, Brown TT, Patel KV, Leng SX, Kirk GD. Frailty, HIV infection, and mortality in an aging cohort of injection drug users. PLoS One. 2013;8:e54910.PubMedCentralPubMedCrossRef
15.
Althoff KN, Jacobson LP, Cranston RD, Detels R, Phair JP, Li X, Margolick JB, Multicenter ACS. Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men. J Gerontol A Biol Sci Med Sci. 2014;69:189–98.PubMedCrossRef
16.
Erlandson KM, Allshouse AA, Jankowski CM, Duong S, Mawhinney S, Kohrt WM, Campbell TB. Comparison of functional status instruments in HIV-infected adults on effective antiretroviral therapy. HIV Clin Trials. 2012;13:324–34.PubMedCentralPubMedCrossRef
17.
18.
Terzian AS, Holman S, Nathwani N, Robison E, Weber K, Young M, Greenblatt RM, Gange SJ. Women’s Interagency HIV Study. Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of ART. J Womens Health (Larchmt). 2009;18:1965–74.CrossRef
19.
Pathai S, Gilbert C, Weiss HA, Cook C, Wood R, Bekker LG, Lawn SD. Frailty in HIV-infected adults in South Africa. J Acquir Immune Defic Syndr. 2013;62:43–51.PubMedCentralPubMedCrossRef
20.
Adeyemi O, Livak B. Higher Veterans Aging Cohort Study (VACS) index scores in HIV-positive adults with CD4 counts <200 cells/mm3 despite viral suppression. J Acquir Immune Defic Syndr. 2013;63:e78–81.PubMedCrossRef
21.
Onen NF, Overton ET. A review of premature frailty in HIV-infected persons; another manifestation of HIV-related accelerated aging. Curr Aging Sci. 2011;4:33–41.PubMedCrossRef
22.
Erlandson KM, Allshouse AA, Jankowski CM, Lee EJ, Rufner KM, Palmer BE, Wilson CC, MaWhinney S, Kohrt WM, Campbell TB. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. JID. 2013;208:249–59.PubMedCentralPubMedCrossRef
23.
Rickbaugh TM, Kilpatrick RD, Hultin LE, Hultin PM, Hausner MA, Sugar CA, Althoff KN, Margolick JB, Rinaldo CR, Detels R, Phair J, Effros RB, Jamienson BD. The dual impact oh HIV-1 infection and aging on naïve CD4 + T-cells: additive and distinct patterns of impairment. PLoS One. 2011;6:e16459.CrossRef
24.
Viard JP, Macroft A, Chiesi A, Kirk O, Røge B, Panos G, Vetter N, Bruun JN, Johnson M, Lundgren JD. EuroSIDA Study Group. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis. 2001;183:1290–4.PubMedCrossRef
25.
Teixeira L, Valdez H, McCune JM, Koup RA, Badley AD, Hellerstein MK, Napolitano LA, Douek DC, Mbisa G, Deeks S, Harris JM, Barbour JD, Gross BH, Francis IR, Halvorsen R, Asaad R, Lederman MM. Poor CD4 cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS. 2001;15:1749–56.PubMedCrossRef
26.
Alcaide ML, Parmigiani A, Pallikkuth S, Roach M, Freguja R, Della Negra M, Bolivar H, Fischi MA, Pahwa S. Immune activation in HIV-infected aging women on antiretrovirals-Implication for age-associated comorbidities: a cross-sectional pilot study. PLoS One. 2013;8:e63804.PubMedCentralPubMedCrossRef
27.
Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, Bertisch B, Bernasconi E, Weber R. Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53:1130–9.PubMedCrossRef
28.
Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, Berti A, Rossi E, Roverato A, Palella F. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–6.PubMedCrossRef
29.
Kendall CE, Wong J, Taljaard M, Glazier RH, Hogg W, Younger J, Manuel DG. A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario. BMC Public Health. 2014;13:161. doi:10.​1186/​1471-2458-14-161.CrossRef
30.
De Socio GV, Ricci E, Parruti G, Maggi P, Madeddu G, Quirino T, Bonfanti P. Chronological and biological age in HIV infection. J Infect. 2010;61:428–30.PubMedCrossRef
31.
De Socio GV, Ricci E, Maggi P, Parruti G, Pucci G, Di Biagio A, Calza L, Orofino G, Carenzi L, Cecchini E, Madeddu G, Quirino T, Schillaci G. CISAI Study Group. Prevalence, awareness, treatment, and control rate of hypertension in HIV-infected patients: the HIV-HY study. Am J Hypertens. 2014;27:222–8.PubMedCrossRef
32.
Satlin MJ, Hoover DR, Glesby MJ. Glycemic control in HIV-infected patients with diabetes mellitus and rates of meeting American Diabetes Association management guidelines. AIDS Patient Care STDS. 2011;25:5–12.PubMedCentralPubMedCrossRef
33.
Madeddu G, Fois AG, Calia GM, Babudieri S, Soddu V, Becciu F, Fiori ML, Spada V, Lovigu C, Mannazzu M, Caddeo A, Piras B, Pirina P, Mura MS. Chronic obstructive pulmonary disease: an emerging comorbidity in HIV-infected patients in the HAART era? Infection. 2013;41:347–53.PubMedCrossRef
34.
Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, Butt AA, Bidwell Goetz M, Leaf D, Oursler KA, Rimland D, Rodriguez Barradas M, Brown S, Gibert C, McGinnis K, Crothers K, Sico J, Crane H, Warner A, Gottlieb S, Gottdiener J, Tracy RP, Budoff M, Watson C, Armah KA, Doebler D, Bryant K, Justice AC. HIV Infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614–22.PubMedCrossRef
35.
Zanni MV, Fitch KV, Feldpausch M, Han A, Lee H, Lu MT, Abbara S, Ribaudo H, Douglas PS, Hoffmann U, Lo J, Grinspoon SK. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014;28:2061–70.PubMedCentralPubMedCrossRef
36.
Nadkarni GN, Konstantinidis I, Wyatt CM. HIV and the aging kidney. Curr Opin HIV AIDS. 2014;9:340–5.PubMedCrossRef
37.
Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L, di Gregorio S, Puig J, Gómez G, Clotet B, Negredo E. Osteoporosis Study Group High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS. 2010;24:2827–33.PubMedCrossRef
38.
Onen NF, Overton ET, Seyfried W, Stumm ER, Snell M, Mondy K. Tebas P Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials. 2010;11:100–9.PubMedCrossRef
39.
Castronuovo D, Cacopardo B, Pinzone MR. Bone disease in the setting of HIV infection:update and review of the literature. Eur Rev Med Pharmacol Sci. 2013;17:2413–9.PubMed
40.
41.
Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclasto-genesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106:1481–8.PubMedCentralPubMedCrossRef
42.
Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H, ASSERT Study Group. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963–72.PubMedCrossRef
43.
Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, Wang H, Callebaut C, Martin H, Fordyce MW, McCallister S. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67:52–8.PubMedCrossRef
44.
Kearney F, Moore AR, Donegan CF, Lambert J. The ageing of HIV: implications for geriatric medicine. Age Ageing. 2010;39:536–41.PubMedCrossRef
45.
Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte AD, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–41.PubMedCrossRef
46.
Warriner AH, Burkholder GA, Overton ET. HIV-related metabolic comorbidities in the current ART era. Infect Dis Clin N Am. 2014;28:457–76.CrossRef
47.
McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol. 2010;67:699–714.PubMed
48.
Valcour VG. HIV, aging, and cognition: emerging issues. Top Antivir Med. 2013;21:119–23.PubMed
49.
Ciccarelli N, Fabbiani M, Grima P, Falasca K, Tana M, Baldonero E, Colafigli M, Silveri MC, Vecchiet J, Cauda R, Di Giambenedetto S. Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients. Infection. 2013;41:1103–9.PubMedCrossRef
50.
Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group, HNRC Group. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3–16.PubMedCentralPubMedCrossRef
51.
Calcagno A, Alberione MC, Romito A, Imperiale D, Ghisetti V, Audagnotto S, Lipani F, Raviolo S, Di Perri G, Bonora S. Prevalence and predictors of blood-brain barrier damage in the HAART era. J Neurovirol. 2014;20:521–5. doi:10.​1007/​s13365-014-0266-2 Epub 2014 Jun 28.PubMedCrossRef
52.
Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med. 2011;19:137–42.PubMedPubMedCentral
53.
Marquine MJ, Umlauf A, Rooney AS, Fazeli PL, Gouaux BD, Paul Woods S, Letendre SL, Ellis RJ, Grant I, Moore DJ, HIV Neurobehavioral Research Program (HNRP) Group. The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment. J Acquir Immune Defic Syndr. 2014;65:190–7.PubMedCentralPubMedCrossRef
54.
Sherr L, Clucas C, Harding R, Sibley E, Catalan J. HIV and depression–a systematic review of interventions. Psychol Health Med. 2011;16:493–527.PubMedCrossRef
55.
Albini L, Calabresi A, Gotti D, Ferraresi A, Festa A, Donato F, Magoni M, Castelli F, Quiros-Roldan E. Burden of non-AIDS-defining and non-virus-related cancers among HIV-infected patients in the combined antiretroviral therapy era. AIDS Res Hum Retroviruses. 2013;29:1097–104.PubMedCrossRef
56.
Helleberg M, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Gerstoft J, Obel N. Causes of death among Danish HIV patients compared with population controls in the period 1995–2008. Infection. 2012;40:627–34.PubMedCrossRef
57.
Ehren K, Hertenstein C, Kümmerle T, Vehreschild JJ, Fischer J, Gillor D, Wyen C, Lehmann C, Cornely OA, Jung N, Gravemann S, Platten M, Wasmuth JC, Rockstroh JK, Boesecke C, Schwarze-Zander C, Fätkenheuer G. Causes of death in HIV-infected patients from the Cologne-Bonn cohort. Infection. 2014;42:135–40.PubMedCrossRef
58.
Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, Grigg R, Hylton T, Pawlish KS, McNeel TS, Goedert JJ. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123:187–94.PubMedCrossRef
59.
60.
61.
Reeve E, Wiese MD, Mangoni AA. Alterations in drug disposition in older adults. Expert Opin Drug Metab Toxicol. 2015:1–18 (Epub ahead of print). PubMed PMID: 25600059.
62.
Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging. 2014;1:2079–86.
63.
Holtzman C, Armon C, Tedaldi E, Chmiel JS, Buchacz K, Wood K, Brooks JT, The HOPS Investigators. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population. J Gen Intern Med. 2013;28:1302–10.PubMedCentralPubMedCrossRef
64.
Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Khoo S, Battegay M, Elzi L, Swiss HIV, Cohort Study Members. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother. 2011;66:2107–11.PubMedCrossRef
65.
66.
McLachlan AJ, Pont LG. Drug metabolism in older people–a key consideration in achieving optimal outcomes with medicines. J Gerontol A Biol Sci Med Sci. 2012;67:175–80.PubMedCrossRef
67.
Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2013;24:1519–27.PubMedCentralPubMedCrossRef
68.
Poizot-Martin I, Solas C, Allemand J, Obry-Roguet V, Pradel V, Bregigeon S, Faucher O, Lacarelle B. Renal impairment in patients receiving a tenofovir-ART regimen: impact of tenofovir trough concentration. J Acquir Immune Defic Syndr. 2013;62:375–80.PubMedCrossRef
69.
Calcagno A, de Gonzalez Requena D, Simiele M, D’Avolio A, Tettoni MC, Salassa B, Orofino G, Bramato C, Libanore V, Motta I, Bigliano P, Orsucci E, Di Perri G, Bonora S. Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function. Antimicrob Agents Chemother. 2013;57:1840–3.PubMedCentralPubMedCrossRef
70.
Kakuda TN, Wade JR, Snoeck E, Vis P, Schöller-Gyüre M, Peeters MP, Corbett C, Nijs S, Vingerhoets J, Leopold L, De Smedt G, Woodfall BJ, Hoetelmans RM. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. Clin Pharmacol Ther. 2010;88:695–703.PubMedCrossRef
71.
Crawford KW, Spritzler J, Kalayjian RC, Parsons T, Landay A, Pollard R, Stocker V, Lederman MM, Flexner C, AIDS Clinical Trials Protocol 5015 Team. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses. 2010;26:635–43.PubMedCentralPubMedCrossRef
72.
Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B, Nelson M, Gilson R, Orkin C, Johnson M, Palfreeman A, Chadwick D, Leen C, Schwenk A, Anderson J, Gompels M, Dunn D, Khoo S, Sabin C, UK Collaborative HIV Cohort Study. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother. 2013;68:1354–9.PubMed
73.
Cattaneo D, Baldelli S, Cerea M, Landonio S, Meraviglia P, Simioni E, Cozzi V, Fucile S, Gazzaniga A, Clementi E, Galli M, Rizzardini G, Gervasoni C. Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing. Antimicrob Agents Chemother. 2012;56:6132–6.PubMedCentralPubMedCrossRef
74.
Croteau D, Letendre S, Best B, Clifford D, Gelman B, Marra C, McArthur J, McCutchan JA, Simpson D, Grant I. Older age is associated with higher ARV concentrations in CSF in HIV + individuals. 19th conference on retroviruses and opportunistic infections. 2012. Seattle (abstract 592).
75.
Gervasoni C, Meraviglia P, Landonio S, Riva A, Galli M, Rizzardini G, Cattaneo D. Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women. J Antimicrob Chemother. 2013;68:1206–7.PubMedCrossRef
76.
Dumond JB, Nicol MR, Kendrick RN, Garonzik SM, Patterson KB, Cohen MS, Forrest A, Kashuba AD. Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. Clin Pharmacokinet. 2012;51:809–22.PubMedCentralPubMedCrossRef
77.
Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496–505. doi:10.​1086/​655681.PubMedCrossRef
78.
Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E, Honda H, Tanuma J, Yazaki H, Tsukada K, Honda M, Teruya K, Kikuchi Y, Oka S. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One. 2011;6:e22661.PubMedCentralPubMedCrossRef
79.
80.
El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. Strategies for Management of Antiretroviral Therapy (SMART) Study Group CD4 + count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–96.PubMedCrossRef
81.
Tripathi A, Liese AD, Winniford MD, Jerrell JM, Albrecht H, Rizvi AA, Zhang J, Duffus WA. Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV-infected adults. Clin Cardiol. 2014;37:517–22.PubMedCrossRef
82.
Sabin C, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D’Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417–26.PubMedCrossRef
83.
Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, Pedersen C, Gerstoft J, Sørensen HT. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Medicine. 2010;11:130–6.PubMedCrossRef
84.
Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17–24.CrossRef
85.
Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram V, Wein N, Holodniy M, Hou N, Owens DK, Desai M. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One. 2013;8:e59551.PubMedCentralPubMedCrossRef
86.
Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV. Impact of individuals antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170:1228–38.PubMedCrossRef
87.
Bedimo R, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011;53:84–91.PubMedCrossRef
88.
Brothers C, Hernandez J, Cutrell A, Curtis L, Ait-Khaled M, Bowlin SJ, Hughes SH, Yeo JM, Lapierre DH. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009;51:20–8.PubMedCrossRef
89.
Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, Mengoli C, Parisi SG, Moyle G. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS. 2011;25:1993–2004.PubMedCrossRef
90.
Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, Marcus KA. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acuqir Immune Defic Syndr. 2012;61:441–7.CrossRef
91.
Martin A, Amin J, Cooper DA, Carr A, Kelleher AD, Bloch M, Baker D, Woolley I, Emery S, STEAL study group. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS. 2010;24:2657–63.PubMedCrossRef
92.
Martınez E, Larrousse M, Podzamczer D, Perez I, Gutierrez F, Lonca´ M, Barragán P, Deulofeu R, Casamitjana R, Mallolas J, Pich J, Gatell JM, BICOMBO Study Team. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS. 2010;24:F1–9.PubMedCrossRef
93.
Jong E, Meijers JC, van Gorp EC, Spek CA, Mulder JW. Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir. AIDS Res Ther. 2010;16:7–9.
94.
Baum PD, Sullam PM, Stoddart CA, McCune JM. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS. 2011;25:2243–8.PubMedCentralPubMedCrossRef
95.
Wohl DA, Arnoczy G, Fichtenbaum CJ, Campbell T, Taiwo B, Hicks C, McComsey GA, Koletar S, Sax P, Tebas P, Ha B, Massengale K, Walsh K, Stein JH. Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther. 2014;19:141–7.PubMedPubMedCentralCrossRef
96.
97.
Marcotullio S, Andreoni M, Antinori A, d’Arminio Monforte A, Di Perri G, Galli M, Ippolito G, Perno CF, Rizzardini G, Lazzarin A, Rapporteur Committee, Cinque P, Fares G, Foglia E, Gervasoni C, Murri R, Nozza S, Rusconi S. The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. New Microbiol. 2012;35:259–77.PubMed
98.
Reynes J, Trinh R, Pulido F, Soto-Malave R, Gathe J, Qaqish R, Tian M, Fredrick L, Podsadecki T, Norton M, Nilius A. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses. 2013;29:256–65.PubMed
99.
Nozza S, Galli L, Antinori A, Chiappetta S, Mazzotta F, Zaccarelli M, Ottou S, De Battista D, Pogliaghi M, Di Pietro M, Malnati M, Ripa M, Bonora S, Lazzarin A. VEMAN Study Group. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study. Clin Microbiol Infect. 2014. doi:10.​1016/​j.​cmi.​2014.​12.​006 pii: S1198-743X(14)00142-6.
100.
Calcagno A, Nozza S, de Gonzalez Requena D, Galli A, D’Avolio A, Simiele M, Chiappetta S, Di Perri G, Lazzarin A, Bonora S. Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. J Antimicrob Chemother. 2013;68:1686–8.PubMedCrossRef
101.
Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, Mohapi L, Martin A, Kerr S, Sohn AH, Teppler H, Van de Steen O, Molina JM, Emery S, Cooper DA. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet. 2013;381:2091–9.PubMedCrossRef
102.
Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, on behalf NEAT001/ANRS143 Study Group. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384:1942–51. doi:10.​1016/​S0140-6736(14)61170-3.PubMedCrossRef
103.
Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A, NEAT001/ANRS143 Study Group. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384:1942–51.PubMedCrossRef
104.
Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, Raffi F, Benetucci J, Mancini M, Yang R, Wirtz V, Percival L, Zhang J, Zhu L, Arikan D, Farajallah A, Nguyen BY, Leavitt R, McGrath D, Lataillade M, The Spartan Study Team. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results. HIV Clin Trials. 2012;13:119–30.PubMedCrossRef
105.
Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Endo T, Horiba M, Koga M, Naito T, Itoda I, Tei M, Fujii T, Takada K, Yamamoto M, Miyakawa T, Tanabe Y, Mitsuya H, Oka S, SPARE study team. Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial. PLoS One. 2013;8:e73639.PubMedCentralPubMedCrossRef
106.
Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, D’Avino A, Mondi A, Cingolani A, Tamburrini E, Murri R, Navarra P, Cauda R, De Luca A. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study). J Antimicrob Chemother. 2013;68:1364–72.PubMedCrossRef
107.
Reliquet V, Chirouze C, Allavena C, Muret P, Peytavin G, André-Garnier E, Bettinger D, Ferré V, Hoen B, Raffi F. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients. Antivir Ther. 2014;19:117–23.PubMedCrossRef
108.
Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, Wan H, Walker ML, Xu X, Zhao J, Teppler H, Dinubile MJ, Rodgers AJ, Nguyen BY, Leavitt R, Sklar P, STARTMRK Investigators. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53:807–16.PubMedCrossRef
109.
Landovitz RJ, Ribaudo HJ, Ofotokun I, Wang H, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS, Lennox JL for the A5257 Study Team. Efficacy and tolerability of atazanvir, raltegravir, or darunavir with FTC/Tenofovir: ACTG 5257. 21st Conference on retroviruses and opportunistic infections. 2014 (abstract #85).
110.
Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S, SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week, results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735–43.PubMedCrossRef
111.
Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, SINGLE Investigators. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807–18.PubMedCrossRef
112.
Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S, ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383:2222–3.PubMedCrossRef
113.
Curtis G, Nichols C, Stainsby J, Lim, Aylott A, Wynne B, Clark A, Bloch M, Maechler G, Martin-Carpenter L, Raffi F, Min S. Dolutegravir: clinical and laboratory safety in integrase inhibitor–naive patients. HIV Clin Trials. 2014;15:199–208.PubMedCrossRef
114.
Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-boosted Darunavir-based regimens over 48 weeks. Clin Drug Investig. 2015;. doi:10.​1007/​s40261-014-0266-2.PubMedCentralPubMed
115.
Theou O, Stathokostas L, Roland KP, Jakobi JM, Patterson C, Vandervoort AA, Jones GR. The effectiveness of exer-cise interventions for the management of frailty: a systematic review. J Aging Res. 2011;2011:569194.PubMedCentralPubMedCrossRef
116.
Gill TM, Baker DI, Gottschalk M, Peduzzi PN, Allore H, Byers A. A program to prevent functional decline in physically frail, elderly persons who live at home. N Engl J Med. 2002;347:1068–74.PubMedCrossRef
117.
Fiatarone MA, O’Neill EF, Ryan ND, Clements KM, Solares GR, Nelson ME, Roberts SB, Kehayias JJ, Lipsitz LA, Evans WJ. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med. 1994;330:1769–75.PubMedCrossRef
118.
Forster A, Lambley R, Hardy J, Young J, Smith J, Green J, Burns E. Rehabilitation for older people in long-term care. Cochrane Database Syst Rev. 2009;1 (CD004294).
119.
Longo V, Bonato M, Bossolasco S, Laura Galli, Andrea Caumo, Gaspare Pavei, Adriano Lazzarin, Giampiero Merati, Antonio LaTorre, Paola Cinque. Brisk walking improves inflammatory markers in ART-treated patients. CROI. 2104 (abstract 763).
120.
Lin AL, Coman D, Jiang L, Rothman DL, Hyder F. Caloric restriction impedes age-related decline of mitochondrial function and neuronal activity. J Cereb Blood Flow Metab. 2014;34:1440–3.PubMedCentralPubMedCrossRef
121.
Farazi M, Nguyen J, Goldufsky J, Linnane S, Lukaesko L, Weinberg AD, Ruby CE. Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging. Cancer Immunol Immunother. 2014;63:615–26.PubMedCentralPubMedCrossRef
122.
Soare A, Weiss EP, Pozzilli P. Benefits of caloric restriction for cardiometabolic health, including type 2 diabetes mellitus risk. Diabetes Metab Res Rev. 2014;30:41–7.PubMedCrossRef
123.
Rizza W, Veronese N, Fontana L. What are the roles of calorie restriction and diet quality in promoting healthy longevity? Ageing Res Rev. 2014;13:38–45.PubMedCrossRef
124.
125.
Lorenzini A. How much should we weigh for a long and healthy life span? the need to reconcile caloric restriction versus longevity with body mass index versus mortality data. Front Endocrinol (Lausanne). 2014;30:121.
126.
Sohal RS, Forster MJ. Caloric restriction and the aging process: a critique. Free Radic Biol Med. 2014;73:366–82.PubMedCrossRef
127.
Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, D’Agostino D, Planavsky N, Lupfer C, Kanneganti TD, Kang S, Horvath TL, Fahmy TM, Crawford PA, Biragyn A, Alnemri E, Dixit VD. The ketone metabolite -hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015 (Epub ahead of print).
128.
129.
Leenders M, van Loon LJ. Leucine as a pharmaconutrient to prevent and treat sarcopenia and type 2 diabetes. Nutr Rev. 2011;69:675–89.PubMedCrossRef
130.
Qin LQ, Xun P, Bujnowski D, Daviglus ML, Van HL, Stamler J, He K. Higher branched-chain amino acid intake is associated with a lower prevalence of being overweight or obese in middle aged East Asian and western adults. J Nutr. 2011;141:249–54.PubMedCentralPubMedCrossRef
131.
Cavuoto P, Fenech MF. A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension. Cancer Treat Rev. 2012;38:726–36.PubMedCrossRef
132.
McPherson RA, Hardy G. Clinical and nutritional benefits of cysteine-enriched protein supplements. Curr Opin Clin Nutr Metab Care. 2011;14:562–8.PubMedCrossRef
133.
134.
Gualano B, Roschel H, Lancha-Jr AH, Brightbill CE, Rawson ES. In sickness and in health: the widespread application of creatine supplementation. Amino Acids. 2012;43:519–29.PubMedCrossRef
135.
Bollhalder L, Pfeil AM, TomonagaY Schwenkglenks M. A systematic literature review and meta-analysis of randomized clinical trials of parenteral glutamine supplementation. Clin Nutr. 2013;32:213–23.PubMedCrossRef
136.
Kitamura A, Tsurugizawa T, Uematsu A, Torii K, Uneyama H. New therapeutic strategy for amino acid medicine: effects of dietary glutamate on gut and brain function. J Pharmacol Sci. 2012;118:138–44.PubMedCrossRef
137.
138.
Smith RL, de Boer R, Brul S, Budovskaya Y, van Spek H. Premature and accelerated aging: HIV or HAART? Front Genet. 2013;28:328.
139.
Biagi E, Candela M, Turroni S, Garagnani P, Franceschi C, Brigidi P. Ageing and gut microbes: perspectives for health maintenance and longevity. Pharmacol Res. 2013;69:11–20.PubMedCrossRef
140.
Klatt NR, Canary LA, Sun X, et al. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest. 2013;123:903–7.PubMedCentralPubMed
141.
Ortiz AM, Klase ZA, Carmack KM, et al. Probiotic and IL-21 treatment promotes Th17 cell recovery in ARV-treatment of pigtail macaques. CROI. 2014 (abstract 83).
142.
Gori A, Rizzardini G, Van Land B, et al. Specific probiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults. Results of the ‘COPA’ pilot randomized trial. Mucosal Immunol. 2011;4:554–63.PubMedCentralPubMedCrossRef
143.
Wilson NL, Moneyham LD, Alexandrov AW. A systematic review of probiotics as a potential intervention to restore gut health in HIV infection. J Assoc Nurses AIDS Care. 2013;24:98–111.PubMedCrossRef
144.
Gonzalez-Hernandez LA, Jave-Suarez LF, Fafutis-Morris M, et al. Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: a double-blind randomized controlled pilot trial. Nutr J. 2012;11:90.PubMedCentralPubMedCrossRef
145.
Stiksrud B, Nowak P, Kvale D, et al. Decreased levels of D-Dimer after probiotic supplementation in patients receiving ART. CROI. 2014 (abstract 342).
146.
Overton E, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, Ribaudo HJ, Tebas P. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013;56:1471–9.PubMedCentralPubMedCrossRef
147.
Rasmussen LD, Kronborg G, Larsen CS, Pedersen C, Gerstoft J, et al. Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. PLoS One. 2013;8:e52828.PubMedCentralPubMedCrossRef
148.
Funderburg N, Jiang Y, Debanne S, Storer N, Labbato D, Clagett B, Robinson J, Lederman M, McComsey G, McComsey G. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin infect Dis. 2014;58:588–9.PubMedCentralPubMedCrossRef
149.
Eckard AR, Jiang Y, Debanne S, Funderburg N, McComsey G. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014;209:1156–64.PubMedCentralPubMedCrossRef
150.
Longenecker CT, Hileman Co Storer NJ, et al. Rosuvastatin lowers cystatin c in HIV-infected subjects on antiretroviral therapy. SATURN-HIV (abstract 743).
151.
Skaaby T, Husemoen LL, Pisinger C, Jorgensen T, Thuesen BH, Fenger M, et al. Vitamin D status and cause-specific mortality: a general population study. PLoS One. 2012;7:e52423.PubMedCentralPubMedCrossRef
152.
Schottker B, Ball D, Gellert C, Brenner H. Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Res Rev. 2013;12:708–18.PubMedCrossRef
153.
Shardell M, Hicks GE, Miller RR, Kritchevsky S, Andersen D, Bandinelli S, Cherubini A, Ferrucci L. Association of low vitamin D levels with the frailty syndrome in men and women. J Gerontol A Biol Sci Med Sci. 2009;64:69–75.PubMedCrossRef
154.
Escota GV, Cross S, Powderly WG. Vitamin D and calcium abnormalities in the HIV-infected population. Endocrinol Metab Clin North Am. 2014;43:743–67.PubMedCrossRef
155.
156.
Havers F, Smeaton L, Gupte N, Detrick B, Bollinger RC, Hakim J, Kumarasamy N, Andrade A, Christian P, Lama JR, Campbell TB, Gupta A, ACTG PEARLS, NWCS 319 Study Teams. 25-Hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings. J Infect Dis. 2014;210:244–53.PubMedCentralPubMedCrossRef
157.
Shepherd L, Souberbielle JC, Bastard JP, Fellahi S, Capeau J, Reekie J, Reiss P, Blaxhult A, Bickel M, Leen C, Kirk O, Lundgren JD, Mocroft A, Viard JP, EuroSIDA in EuroCOORD. Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. J Infect Dis. 2014;210:234–43.PubMedCrossRef
158.
Piconi S, Parisotto S, Rizzardini G, Passerini P, Terzi R, Argenteri B, Meraviglia P, Capetti A, Biasin M, Trabattoni D, Clerici M. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy–treated immunologic nonresponders. Blood. 2011;118:3263–72.PubMedCrossRef
159.
Pettersen FO, Torheim EA, Dahm AE, Aaberge IS, Lind A, Holm M, Aandahl EM, Sandset PM, Taskén K, Kvale D. An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J Virol. 2011;85:6557–66.PubMedCentralPubMedCrossRef
160.
161.
Sereti I, Estes JD, Thompson WL, Morcock, Fischl MA, Croughs T, Beq S, de Lafaye Micheaux S, Yao MD, Ober A, Wilson EM, Natarajan V, Imamichi H, Boulassel MR, Lederman MM, Routy JP. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog. 2014;10:e1003890.PubMedCentralPubMedCrossRef
162.
Cimbro R, Vassena L, Arthos J, Cicala C, Kehrl JH, Park C, Sereti I, Lederman MM, Fauci AS, Lusso P. IL-7 induces expression and activation of integrin α4β7 promoting naive T-cell homing to the intestinal mucosa. Blood. 2012;120:2610–9.PubMedCentralPubMedCrossRef
163.
Schuetz A, Phuang-Ngern Y, Rerknimitr R, et al. Early ART initiation prevents disruption of the mucosal barrier and subsequent T-Cell activation. CROI. 2014 (abstract 77).
164.
Massanella M, Llibre JM, Marfil S, et al. Effect of Raltegravir intensification in the cytokine profile of treated HIV + individuals. CROI. 2014 (abstract 300).
165.
Cipriani S, Francisci D, Mencarelli A, Renga B, Schiaroli E, D’Amore C, Baldelli F, Fiorucci S. Efficacy of the CCR5 antagonist maraviroc in reducing early Ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation. 2013;127:2114–24.PubMedCrossRef
166.
Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4 + T cell recovery on antiretroviral therapy. J Infect Dis. 2011;203:1474–83.PubMedCentralPubMedCrossRef
167.
Cahn P, Ruxrungtham K, Gazzard B, Diaz RS, Gori A, Kotler DP, Vriesema A, Georgiou NA, Garssen J, Clerici M, Lange JM, (BTE) Blinded Nutritional Study for Immunity and Tolerance Evaluation Study Team. The immunomodulatory nutritional intervention NR100157 reduced CD4 + T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study). Clin Infect Dis. 2013;57:139–46.PubMedCrossRef
168.
Sperber K, Quraishi H, Kalb TH, Panja A, Stecher V. Mayer L Selective regulation of cytokine by hydroxychloroquine: inhibition of interleukin-1 alpha (IL-1 alpha) and IL-6 in human monocytes and T cells. J Rheumatol. 1993;20:803–8.PubMed
169.
Routy JP, Angel J, Patel M, Kanagaratham C, Radzioch D, Kema I, Gilmore N, Ancuta P, Singer J, Jenabian MA. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy. HIV Med. 2015;16:48–56.PubMedCrossRef
170.
Shan L, Siliciano RF. Unraveling the relationship between microbial translocation and systemic immune activation in HIV infection. J Clin Invest. 2014;124:2368–71.PubMedCentralPubMedCrossRef
171.
Kristoff J, Haret-Richter G, Ma D, Ribeiro RM, Xu C, Cornell E, Stock JL, He T, Mobley AD, Ross S, Trichel A, Wilson C, Tracy R, Landay A, Apetrei C, Pandrea I. Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. J Clin Invest. 2014;124:2802–6.PubMedCentralPubMedCrossRef
172.
Sandler NG, Zhang X, Bosch RJ, Funderburg NT, Choi AI, Robinson JK, Fine DM, Coombs RW, Jacobson JM, Landay AL, Douek DC, Tressler R, Read SW, Wilson CC, Deeks SG, Lederman MM, Gandhi RT, AIDS Clinical Trials Group A5296 Team. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis. 2014;210:1549–54.PubMedPubMedCentralCrossRef
173.
Hunt PW, Shulman NS, Hayes TL, Dahl V, Somsouk M, Funderburg NT, McLaughlin B, Landay AL, Adeyemi O, LE Gilman, Clagett B, Rodriguez B, Martin JN, Schacker TW, Shacklett BL, Palmer S, Lederman MM, Deeks SG. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4 + T-cell recovery: a randomized trial. Blood. 2013;121:4635–46.PubMedCentralPubMedCrossRef
174.
Fowler BJ, Gelfand BD, Kim Y, Kerur N, Tarallo V, Hirano Y, Amarnath S, Fowler DH, Radwan M, Young MT, Pittman K, Kubes P, Agarwal HK, Parang K, Hinton DR, Bastos-Carvalho A, Li S, Yasuma T, Mizutani T, Yasuma R, Wright C, Ambati J. Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity. Science. 2014;346:1000–3.PubMedCentralPubMedCrossRef
Metadata
Title
Ageing with HIV: a multidisciplinary review
Authors
A. Calcagno
S. Nozza
C. Muss
B. M. Celesia
F. Carli
S. Piconi
G. V. De Socio
A. M. Cattelan
G. Orofino
D. Ripamonti
A. Riva
G. Di Perri
Publication date
01-10-2015
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 5/2015
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-015-0795-5

Other articles of this Issue 5/2015

Infection 5/2015 Go to the issue

Case Report

A rare case of Waterhouse-Friderichsen syndrome caused by Capnocytophaga canimorsus in an immunocompetent patient

Case Report

Guillain-Barré syndrome associated with Mycobacterium bovis lymphadenitis

Case Report

Rapid reduction of viruria and stabilization of allograft function by fusidic acid in a renal transplant recipient with JC virus-associated nephropathy

Original Paper

Prevalence of intestinal parasite infections and associated clinical symptoms among patients with end-stage renal disease undergoing hemodialysis

Case Report

Recipient-born bloodstream infection due to extensively drug-resistant Acinetobacter baumannii after emergency heart transplant: report of a case and review of the literature

Images in Infection

Umbolith: a cause of umbilical discharge and omphalitis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits